Financial Review: GBS (NYSE:GBS) vs. GlucoTrack (NASDAQ:GCTK)

GlucoTrack (NASDAQ:GCTK) and GBS (NYSE:GBS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares GlucoTrack and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-826.43%	-325.85%
GBS	N/A	-85.64%	-54.42%

Insider & Institutional Ownership

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 2.8% of GBS shares are owned by institutional investors. 17.7% of GlucoTrack shares are owned by insiders. Comparatively, 0.3% of GBS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares GlucoTrack and GBS”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$7.10 million	($2.05)	-1.06
GBS	$440,000.00	50.76	-$8.31 million	($0.56)	-2.68

GlucoTrack has higher earnings, but lower revenue than GBS. GBS is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for GlucoTrack and GBS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	0	0	0	0	N/A
GBS	0	0	0	0	N/A

Risk and Volatility

GlucoTrack has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Summary

GBS beats GlucoTrack on 5 of the 9 factors compared between the two stocks.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.